Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor-Reference-Cited by-同舟云学术

Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor

Published:2019-05-15 Issue:7 Volume:9 Page:926-943
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

To Ciric,Jang Jaebong,Chen Ting,Park Eunyoung,Mushajiang Mierzhati,De Clercq Dries J.H.,Xu Man,Wang Stephen,Cameron Michael D.,Heppner David E.^ORCID,Shin Bo Hee^ORCID,Gero Thomas W.,Yang Annan,Dahlberg Suzanne E.,Wong Kwok-Kin,Eck Michael J.,Gray Nathanael S.,Jänne Pasi A.

Funder

HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI)

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 240 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis, and biological evaluation of diphenyl ether substituted quinazolin-4-amine derivatives as potent EGFRL858R/T790M/C797S inhibitors;European Journal of Medicinal Chemistry;2024-12

2. Synthesis, In Silico Prediction, and In Vitro Evaluation of Anti-tumor Activities of Novel 4'-Hydroxybiphenyl-4-carboxylic Acid Derivatives as EGFR Allosteric Site Inhibitors;Current Medicinal Chemistry;2024-11

3. Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer;European Journal of Medicinal Chemistry;2024-11

4. BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors;npj Precision Oncology;2024-09-11

5. Discovery of a potent, selective, and orally available EGFR C797S mutant inhibitor (DS06652923) with in vivo antitumor activity;Bioorganic & Medicinal Chemistry;2024-09